Up to 6 years after receiving a single treatment with the gene therapy product lipoprotein lipase (LPL), patients with the debilitating genetic disease LPL deficiency (LPLD) had about 50% fewer episodes of pancreatitis than before receiving the treatment. None of the study participants suffered severe pancreatitis following gene therapy and only one required admission to the intensive care unit for treatment of LPLD, which can be fatal, according to a study published in Human Gene Therapy.
↧